ASN-51 is under clinical development by Asceneuron and currently in Phase I for Alzheimer’s Disease. According to GlobalData, Phase I drugs for Alzheimer’s Disease have a 63% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ASN-51’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ASN-51 overview
ASN-51 is under development for the treatment of Parkinson's disease, Alzheimer’s disease and amyotrophic lateral sclerosis. It is a small molecule act by targeting O-GlcNAcase (O-linked-beta-N-acetylglucosaminidase). It is administered through oral route.
Asceneuron overview
Asceneuron is a biotechnology company that discovers and develops small molecule therapeutics for neurodegenerative diseases such as orphan tauopathies, alzheimer’s and parkinson’s diseases. The company’s pipeline products include O-GLCNACASE inhibitors and M1 PAM. Its O-GLCNACASE inhibitors is used for the treatment of alzheimer’s disease, frontotemporal dementia and progressive supranuclear palsy. Asceneuron focuses on development of orally bio available therapeutics for debilitating neuro degenerative disorders. It partners with contract research organizations to carry out activities in medicinal chemistry. Asceneuron is headquartered in Lausanne, Switzerland.
For a complete picture of ASN-51’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
